Boston Pharma Plays Catch Up To Akero, 89bio In MASH
Competing with two Phase III competitors in the FGF21 analog class, Boston Pharma is hoping to begin Phase III this year. Novo Nordisk poses a new challenge with zalfermin.
Competing with two Phase III competitors in the FGF21 analog class, Boston Pharma is hoping to begin Phase III this year. Novo Nordisk poses a new challenge with zalfermin.